Summit Therapeutics PLC (NASDAQ: SMMT, LON: SUMM) is to present further data showing the superiority of its new antibiotic for hospital superbug C.Diff over the standard of care medicine.
The additional data on Summit's ridinilazole versus vancomycin comes from the from the Phase 2 CoDIFy trial and will be heard at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Taking the antibiotic ridinilazole resulted in a marked reduction in rates of C-Diff recurrence as compared to vancomycin (14.3% versus 34.8%), the drug discovery firm will say.
This result comes on top of the previously reported statistical superiority in 'sustained clinical response' rates of ridinilazole over vancomycin (66.7% compared to 42.4%) for treating the disease.
Sustained clinical response is defined as clinical cure at the end of treatment and no recurrence of the condition in 30 days after therapy.
C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually.
Recurrence is a key problem as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs.
Summit shares were unchanged in London at 96p each.